229 related articles for article (PubMed ID: 38255960)
1. Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro.
Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960
[TBL] [Abstract][Full Text] [Related]
2. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.
Zhang S; Dolgalev I; Zhang T; Ran H; Levine DA; Neel BG
Nat Commun; 2019 Nov; 10(1):5367. PubMed ID: 31772167
[TBL] [Abstract][Full Text] [Related]
3. Serous Tubal Intraepithelial Carcinoma in a Risk-reducing Salpingo-oophorectomy Specimen From a RAD51D Mutation Carrier: A Case Report.
Gregory-Davis KJ; Walker A; Colello LS; McKinnon W; Everett E; Chang MC
Int J Gynecol Pathol; 2023 Jan; 42(1):89-92. PubMed ID: 35149617
[TBL] [Abstract][Full Text] [Related]
4. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
Yucer N; Ahdoot R; Workman MJ; Laperle AH; Recouvreux MS; Kurowski K; Naboulsi DJ; Liang V; Qu Y; Plummer JT; Gayther SA; Orsulic S; Karlan BY; Svendsen CN
Cell Rep; 2021 Dec; 37(13):110146. PubMed ID: 34965417
[TBL] [Abstract][Full Text] [Related]
5. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
6. Two different, mutually exclusively distributed,
Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
[TBL] [Abstract][Full Text] [Related]
7. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
[TBL] [Abstract][Full Text] [Related]
8. Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Maru Y; Tanaka N; Tatsumi Y; Nakamura Y; Yao R; Noda T; Itami M; Hippo Y
J Pathol; 2021 Oct; 255(2):177-189. PubMed ID: 34184756
[TBL] [Abstract][Full Text] [Related]
9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
10. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
[TBL] [Abstract][Full Text] [Related]
11. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
[TBL] [Abstract][Full Text] [Related]
12. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract][Full Text] [Related]
13. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
14. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.
Hoffmann K; Berger H; Kulbe H; Thillainadarasan S; Mollenkopf HJ; Zemojtel T; Taube E; Darb-Esfahani S; Mangler M; Sehouli J; Chekerov R; Braicu EI; Meyer TF; Kessler M
EMBO J; 2020 Mar; 39(6):e104013. PubMed ID: 32009247
[TBL] [Abstract][Full Text] [Related]
15. Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer.
Galhenage P; Zhou Y; Perry E; Loc B; Fietz K; Iyer S; Reinhardt F; Da Silva T; Botchkarev V; Chen J; Crum CP; Weinberg RA; Pathania S
Cell Rep; 2023 Oct; 42(10):113144. PubMed ID: 37729060
[TBL] [Abstract][Full Text] [Related]
16. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
[TBL] [Abstract][Full Text] [Related]
17. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
18. Whence High-Grade Serous Ovarian Cancer.
Kohn EC; Ivy SP
Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
[TBL] [Abstract][Full Text] [Related]
19. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
[TBL] [Abstract][Full Text] [Related]
20. Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.
Chui MH; Vang R; Wang TL; Shih IM; VandenBussche CJ
Cancer Cytopathol; 2019 Mar; 127(3):192-201. PubMed ID: 30861338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
